Chief Scientific Officer and Chief Medical Officer
Dr. Roger Tell is responsible for medical and scientific issues at Isofol. Dr. Tell joined Isofol in February 2019 and has served as the Senior Vice President of Clinical Development and Chief Scientific Officer, and as the Chief Medical Officer since August 2019. He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.
Roger joined Isofol in 2019.
Position: Chief Scientific Officer and Chief Medical Officer
Holdings in Isofol*: 0 shares, 176 300 warrants**
Phone: (+46) 760 293 911
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2019.
** Isofol Medical AB (publ) warrent program 2018 series 2018/2022 and 2018/2023 . For more information and terms read more under Corporate Governance.